WOBURN, Mass. & WILMINGTON, N.C.--(BUSINESS WIRE)--BioTrove Inc. and Gene Express, Inc. today announced an exclusive co-marketing agreement to test market a standardized genetic profiling test for indicators of lung cancer risk. Supported by a two-year National Institutes of Health (NIH) grant, the new profiling test combines BioTrove’s OpenArray® nanofluidic polymerase chain reaction (PCR) technology platform, Gene Express standards for accurate and consistent PCR measurement, and the clinical expertise of the University of Rochester School of Medicine and Dentistry to create the Standardized NanoArray PCR (SNAP) gene expression profiling system – a novel method for consistent and accurate lung cancer risk analysis deployable to diagnostic laboratories or community hospitals.
